Lymphoma,%20Large-Cell,%20Anaplastic
Showing 1 - 25 of >10,000
Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma
Active, not recruiting
- ALK-Positive Anaplastic Large Cell Lymphoma
- RNAseq
-
Toulouse, FranceIUCT-Oncopole University Hospital
Jul 3, 2023
Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma, Non Hodgkin Lymphoma Trial in Cleveland (Med-Jet Injector,
Not yet recruiting
- Mycosis Fungoides of Skin (Diagnosis)
- +5 more
- Med-Jet Injector
- +4 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 17, 2023
DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Active, not recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- +4 more
- EPOCH
- Rituximab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Anaplastic Large Cell Lymphoma, Vinorelbine Trial in Shanghai (Vinorelbine)
Completed
- Anaplastic Large Cell Lymphoma
- Vinorelbine
-
Shanghai, Shanghai, ChinaShanghai Children's Medical Center
Jul 23, 2022
Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma Trial in Seoul
Completed
- Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma
-
Seoul, Gangnam-Gu, Korea, Republic ofSamsung Medical Center
Feb 4, 2022
Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht
Recruiting
- Anaplastic Large Cell Lymphoma, ALK-Positive
- +2 more
-
Paris, France
- +1 more
Sep 27, 2022
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell
Active, not recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +10 more
- Pembrolizumab
- Romidepsin
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Trial in United States
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +14 more
- Cholecalciferol
- Laboratory Biomarker Analysis
-
Scottsdale, Arizona
- +4 more
Jan 16, 2023
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +4 more
- anti-CD7 CAR-T cells
-
Shanghai, ChinaXianmin General Song
Aug 29, 2022
Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Tumors Trial in Frankfurt (Adriamycin, Cyclophosphamide, Cytarabine)
Completed
- Burkitt's Lymphoma
- +4 more
- Adriamycin
- +10 more
-
Frankfurt, GermanyUniversity Hospital, Medical Dept. II
Aug 17, 2022
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,
Recruiting
- Diffuse Large B Cell Lymphoma
- +5 more
- Toripalimab, Rituximab
- R-CHOP Protocol
-
Guangzhou, Guangdong, ChinaDepartment of hematology department, Nanfang hospital
Apr 6, 2022
Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed
Not yet recruiting
- Pediatric Cancer
- +11 more
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
-
Milwaukee, WisconsinChildren's Wisconsin
Sep 14, 2022
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston
Active, not recruiting
- Anaplastic Large Cell Lymphoma
- +4 more
-
Duarte, California
- +3 more
Jul 21, 2022
ALK+ Anaplastic Large Cell Lymphoma Trial in Wien (Brentuximab vedotin, Imatinib)
Terminated
- ALK+ Anaplastic Large Cell Lymphoma
- Brentuximab vedotin
- Imatinib
-
Wien, AustriaUniversitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abte
Feb 15, 2022
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)
Not yet recruiting
- T-Cell Non-Hodgkin Lymphoma
- +14 more
- WU-CART-007
-
Saint Louis, MissouriWashington University School of Medicine
Jan 17, 2023
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail
Recruiting
- T-cell Lymphoma
- +30 more
- Optional Blood Sample
- Optional Nail Sample
-
Duarte, California
- +25 more
Jul 28, 2023
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma
Recruiting
- Anaplastic Large Cell Lymphoma
- +19 more
- Pembrolizumab
- Pralatrexate
-
Duarte, California
- +2 more
Aug 15, 2022
Pediatric Anaplastic Large Cell Lymphoma Trial in Shanghai (P regimen, Course A1 + Vin, Course B1 +Vin)
Recruiting
- Pediatric Anaplastic Large Cell Lymphoma
- P regimen
- +7 more
-
Shanghai, ChinaShanghai Children's Medical Center
Jul 23, 2022
Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell
Active, not recruiting
- Anaplastic Large Cell Lymphoma
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, California
- +1 more
Jul 26, 2022
Extranodal Lymphoma or Lymphoma of Rare Pathological Types
Not yet recruiting
- Lymphoma
- +8 more
- No interventions need to be specified for this study
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 15, 2023
Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and
Recruiting
- Breast Implant-Associated Anaplastic Large Cell Lymphoma
- +2 more
-
London, United Kingdom
- +1 more
Aug 17, 2021
Lymphoma, Large-Cell, Anaplastic, NSCLC Trial (Brigatinib)
Completed
- Lymphoma, Large-Cell, Anaplastic
- Carcinoma, Non-Small-Cell Lung
- (no location specified)
Jul 26, 2021
Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified Trial in Hangzhou (Anti CD30 CAR-T Cell Injection)
Not yet recruiting
- Hodgkin Lymphoma
- +7 more
- Anti CD30 CAR-T Cell Injection
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of medicine, Zhejiang Uni
Jan 12, 2022